Phenotypic Variations of Cartilage Hair Hypoplasia: Granulomatous Skin Inflammation and Severe T Cell Immunodeficiency as Initial Clinical Presentation in Otherwise Well Child with Short Stature

Liza J. McCann · Jo McPartland · Dawn Barge · Lisa Strain · David Bourn · Eduardo Calonje · Julian Verbov · Andrew Riordan · George Kokai · Chris M. Bacon · Michael Wright · Mario Abinun

Received: 9 September 2013 / Accepted: 24 October 2013 / Published online: 12 November 2013
© Springer Science+Business Media New York 2013

Abstract We report a child with short stature since birth who was otherwise well, presenting at 2.8 years with progressive granulomatous skin lesions when diagnosed with severe T cell immunodeficiency. When previously investigated for short stature, and at the time of current investigations, she had no radiological skeletal features characteristics for cartilage hair hypoplasia, but we found a disease causing RMRP (RNase mitochondrial RNA processing endoribonuclease) gene mutation. Whilst

stem cell transplantation (HSCT) was underway, she developed rapidly progressive EBV-related lymphoproliferative disorder requiring laparotomy and small bowel resection, and was treated with anti-B cell monoclonal antibody and eventually curative allogeneic HSCT. Screening for RMRP gene mutations should be part of immunological evaluation of patients with ‘severe and/or combined’ T cell immunodeficiency of unknown origin, especially when associated with short stature and regardless of presence or absence of radiological skeletal features.
Keywords Cartilage-hair hypoplasia · granulomatous inflammation · RNase mitochondrial RNA processing endoribonuclease · severe T cell immunodeficiency · EBV driven lymphoproliferative disease

Abbreviations

CHH Cartilage-hair hypoplasia
RNA Ribonucleic acid
RMRP RNA component of the mitochondrial RNA processing
CID Combined immunodeficiency
HSCT Haematopoietic stem cell transplantation
EBV Epstein–Barr virus
LPD Lymphoproliferative disorder
BCG Bacillus Calmette-Guerin
ESR Erythrocyte sedimentation ratio
CRP C reactive protein
Ig Immunoglobulin
DNA Deoxyribonucleic acid
ENA Extractible nuclear antigen
VCA Virus capsid antigen
CMV Cytomegalovirus
VZV varicella zoster virus
CD Cluster of differentiation
TCR T cell receptor
PCR Polymerase chain reaction
HHV Human herpes virus
HLA Human leukocyte antigen
URD Unrelated donor
GvHD Graft versus host disease
TNF Tumour necrosis factor

Introduction

Cartilage-hair hypoplasia (CHH) (MIM #250250) is a rare autosomal recessive syndrome characterized by clinical features of metaphyseal dysplasia (short-limbed dwarfism) and light-coloured hypoplastic hair, bone marrow failure, defective spermatogenesis, an increased risk of Hirschsprung disease and malignancies, and variable degree of immunodeficiency [1]. CHH is caused by mutations of the untranslated RMRP gene, which encodes for the RNA component of the mitochondrial RNA processing (RMRP) endoribonuclease complex. Disease-causing mutations in RMRP result in disruption of ribosomal processing and cell cycle progression in rapidly dividing cells such as lymphocytes and chondrocytes, thus explaining the pleiotropy of clinical manifestations [2–4].

Despite individual variability, it has been recently shown that functional lymphocyte abnormalities are an integral component of CHH, with defects in thymic generation of T lymphocytes and in peripheral T-cell proliferation, cell cycle control, and activation-induced cell death [5]. In patients with clinical and laboratory features of (severe) T cell and/or combined immunodeficiency (CID) such as failure to thrive, recurrent severe infections (bacterial, fungal, viral), lymphopaenia with absent/low ‘naïve’ T cells and/or T cell function [5, 6], allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative treatment, although the skeletal abnormalities and the growth failure remains unaffected [7].

Here we report progressive granulomatous inflammation as a leading clinical presentation of CHH due to RMRP gene mutation in an otherwise well child with short stature since birth, but no radiological features of skeletal dysplasia, associated with severe T cell immunodeficiency resulting in EBV-related lymphoproliferative disease (LPD), eventually cured by allogeneic HSCT.

Case Report

A 2 year 8 month female, the first child of unrelated Caucasian parents, presented with a 12 months history of initially small painless erythematous lesion affecting the right arm, gradually progressing in size (Fig. 1a–b), and a smaller lesion on the right leg. Except for recent ear infection with fever (38.6 °C), there was no history of infections, bowel symptoms, foreign travel or exposure to mycobacteria (tuberculosis). She was fully vaccinated (except BCG), and had been previously investigated for persistent short stature since birth (height <0.4th percentile with mid-parental height of 50th percentile; weight 2nd percentile) but no underlying reason was found. She was short but proportionate, with fine blond hair, and with normal nails, teeth, body lanugo hair and sweating.

Initial investigations revealed raised inflammatory markers (ESR 96 mm/h; CRP 131 mg/l), significant neutropaenia (ANC 0.01–0.11×10e9/L), non-haemolytic anaemia (Hb 8.6 g/l, negative direct Coombs test, normal serum bilirubin), variable lymphopaenia (3.3–1.95×10e9/L), elevated serum immunoglobulin (Ig) M (4.62 g/l; range 0.5–2.0), and negative antinuclear, double stranded-DNA, ENA and anti-neutrophil antibodies. Bacterial, mycobacterial and fungal cultures (blood, skin) were negative, and viral serology non-diagnostic (positive EBV VCA IgM and IgG, CMV IgG, and negative VZV IgG and Parvovirus B19 IgM and IgG). Chest and bone (skeletal survey) radiography and abdominal ultrasound were normal. Bone marrow aspiration and biopsy (trephine) showed somewhat reduced erythroid series, and a reactive picture with significant left shift and good myeloid activity with increased numbers of eosinophils, although with a lack of maturation. The initial skin biopsy (Fig. 1c–e) demonstrated CD3+ lymphocyte infiltrate and a T cell clone by T cell receptor (TCR) gene rearrangement analysis; EBV in-situ hybridization was negative as were mycobacterial PCR and fungal stains.
Further immunological investigations showed normal neutrophil oxidative burst and protective antibody titres to Haemophilus influenzae type b (1.0 mg/l; range 1.0–20), tetanus (0.66 IU/ml; range 0.1–10) and pneumococcus (>0.35 mcg/l for 11/13 tested strains). However, she was found to have severe T cell immunodeficiency (Table I, Fig. 2) and viral infections (by PCR, EBV 5.5 × 10e4 and HHV6 2 × 10e3 (copies/ml) in blood, sapovirus in stool, adenovirus in nasal swab, and few EBV-positive cells were detected in the second skin biopsy).

Based on the features of short stature since birth, severe T cell immunodeficiency and unusual granulomatous skin inflammation, in spite of normal bone radiography (Fig. 3), we searched for disease-causing mutations in the RMRP gene. Compound heterozyosity for a 13 bp duplication in the promoter (g.–26_–14 dup TACTACTCTGTGA) inherited from the mother (new mutation) and a nucleotide substitution (g.4C>T) close to the transcription initiation site inherited from the father (previously reported) confirmed the diagnosis (2,3). The severe T cell immunodeficiency and persistent EBV viraemia were indications for HSCT. However, before an unrelated (URD) donor was identified she developed abdominal pain and distension, fever and raised CRP (150 mg/l). Exploratory laparotomy revealed an ileal tumorous mass (Fig. 1f) which was resected and confirmed to be EBV-related diffuse large B-cell lymphoma (Fig. 1g–i). She was treated with anti-B cell monoclonal antibody (rituximab), and in June 2012 received 11.1 × 10e6/kg CD34+ peripheral blood stem cells from a 10/10 HLA matched URD after conditioning with alemtuzumab, treosulfan and fludarabine. Engraftment was uneventful (platelets day + 11; neutrophils day + 15) resulting in 100 % donor chimaerism. Complications post-HSCT included transient grade 2 acute (skin, gut) graft versus...
host disease (GvHD) at 3 weeks, treated with corticosteroids and TNF-alpha blocking agent (infliximab), autoimmune cytopenias (Coombs positive haemolytic anaemia, thrombocytopaenia and neutropaenia) at 3 months, treated with corticosteroids, immunomodulatory high-dose intravenous Ig (IVIg) and rituximab, and viral reactivation and/or new infections (parainfluenza III, adenovirus, HHV6, rhinovirus, coronavirus, norovirus) of which only persistent HHV6 viraemia (10^4–10^5/ml) and biopsy-proven enterocolitis needed treatment (ganciclovir, valganciclovir, foscarnet). One year post-HSCT she is well with markedly receded granulomatous skin lesions, on IVIg substitution and azithromycin prophylaxis. Chimaerism remains 100 % donor in myeloid, T and B cell lineages, she has normal numbers of naïve ’early thymic emigrant’ T cells, in vitro proliferation to PHA, and emerging B cells and serum IgM post-rituximab.

Discussion

The clinical features of CHH are more heterogeneous than usually thought [1, 2], with marked variability of immunological phenotype [5, 6, 8] and radiographic features [9]. Importantly for the diagnostic process, as illustrated by our case, the

Table 1 Immunologic parameters I: a/Peripheral blood lymphocyte markers and b/Mitogen stimulated T cell proliferation

| Age        | 2.8 year | 3 year (Post-rituximab) | (NV) |
|------------|----------|-------------------------|------|
| a/Lymphocytes (cells/μl) | 3602 | 909 | (2–8000) |
| CD3+T cells (cells/μl) | 1885 | 721 | (900–4500) |
| CD3+/CD8+ T cells (cells/μl) | 714 | 250 | (300–1600) |
| CD3+/CD4-/CD45RA+/CD27+ (% T cells) | 4 % | 6 % | |
| CD3+/CD4-/CD45RA+/CD27+ (cells/μl) | 75 | 43 | | |
| CD3+/CD4-/CD45RA+/CD27+ (% T cells) | 0 | 0 | |
| CD3+/CD4+ T cells (cells/μl) | 459 | 243 | (500–2400) |
| CD3+/CD4-/CD45RA+/CD27+ (% T cells) | <1 % | <1 % | |
| HLA-DR+/CD3+ T cells (% T cells) | 50 % | 26 % | |
| T cell receptor alpha/beta (% T cells) | 43 % | n/a | |
| T cell receptor gamma/delta (% T cells) | 57 % | n/a | |
| CD19+B cells (cells/μl) | 1064 | 0 | (200–2100) |
| CD19+CD27-IgD+ (% B cells) | 71 % | n/a | |
| CD19+CD27-IgD+ (% B cells) | 22 % | n/a | |
| CD19+CD27-IgD- (% B cells) | 4 % | n/a | |
| CD3-/CD56+/CD16+ NK cells (cells/μl) | 615 | 172 | (100–1000) |
| MHC class I and II expression | Normal | Normal | |
| b/Mitogen stimulated T cell proliferation | | | | |
| Background (cpm) | 2695 | (2741) | |
| PHA | 6429 | (165591) | |
| Anti-CD3 | 106910 | (142813) | |
| PMA+Ionophore | 67039 | (154643) | |
characteristic skeletal abnormalities should not always be expected to be present, particularly in early childhood [9, 10]. Bone marrow failure is common, as in our patient, with hypoplastic anaemia reported in ~80 %, lymphopaenia in ~60 %, and neutropaenia in ~25 % of patients [11]. Skin granulomatous inflammation can be caused by infections (mycobacteria in particular), inflammatory conditions (sarcoidosis, inflammatory bowel disease, Blau syndrome etc.), but may also be a feature of primary immunodeficiency disorders associated with marked immune dysregulation such as common variable immunodeficiency, chronic granulomatous disease, combined/T cell immunodeficiency, etc. [reviewed in 12]. Omenn syndrome has been reported in patients with RMRP mutations [13], and a variety of patients classified as ‘short-limbed skeletal dysplasia with combined immunodeficiency’ (MIM 200900) presented with skin features such as ectodermal dysplasia [14] and granulomatous lesions [15]. Mosbous et al. described inflammatory granulomas as a new clinical feature in 4 out of a series of 21 patients with CHH [16], and a further case of extensive granulomatous lesions was reported recently in a foetus [17]. Similar to ours, these 5 patients with proven RMRP mutation had severe CD4 T cell lymphopaenia [16, 17]. Even in otherwise clinically ‘mild’ phenotype [10], severe T cell lymphopaenia should not be undermined. Our patient clearly demonstrated one of the hallmarks of severely impaired T cell immunity due to RMRP mutation, the poor handling of the herpes family of viruses, with development of life-threatening EBV-related LPD [1, 5].

Fig. 2 Immunologic parameters II: TCR V-beta family pattern. Skewed usage of TCR V-beta family, with increased number of expansions seen in the CD4+ population, and increased number and size of expansions in the CD4- (CD8+) population. See Table Legend for further explanation. CD cluster of differentiation, TCR T cell receptor

![CD3+CD4+ TCR V-beta Family](chart1.png)

![CD3+CD4- TCR V-beta Family](chart2.png)
The only curative therapy is allogeneic HSCT [7], highlighted by the ‘natural history’ observed during the long-term follow-up of a child diagnosed with CHH at the age 8 years, who at the age 32 years presented with relapsing EBV-related anaplastic large cell lymphoma and granulomatous lymphomatoid papulosis, both conditions being part of the spectrum of primary cutaneous CD30+ T cell LPD, and who died 14 years after the primary diagnosis of lymphoma in spite of several courses of chemotherapy [18]. A recent insight in the role of dysregulated long non-coding RNAs in cancer initiation and progression, in the case of RMRP specifically related to leukemia and lymphoma [19] further expands our understanding of the well recognised increased incidence of cancer in patients with CHH, particularly non-Hodgkin lymphoma and basal cell carcinoma [20].

All this evidence strongly suggests that patients with severely impaired T cell immunity due to RMRP mutation should be classified in the group of “severe and/or combined primary immunodeficiencies” [21–24].

Summary

We present a patient with granulomatous lesions and severe T cell immunodeficiency due to RMRP gene mutation, who developed rapidly progressive and life-threatening EBV-related LPD.

Screening for RMRP gene mutations should be part of immunological evaluation of patients with ‘severe and/or combined’ immunodeficiency of unknown origin, especially if associated with short stature and/or granulomatous inflammatory lesions, irrespective of presence or absence of radiographic features characteristic for cartilage hair hypoplasia.

Allogeneic haematopoietic stem cell transplantation is the only curative treatment for immunodeficiency, while growth failure remains unaffected.

Acknowledgments We are grateful to Drs Ali Al-Sharqi, Poonam Dharmaraj, Helen Campbell and Eileen Baildam, Alder Hey Children’s NHS Foundation Trust, Liverpool and the staff at the Children’s Bone Marrow Transplantation Unit, Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, for their involvement in management of the patient.

Declaration of Funding None.

Conflict of Interest The authors declare that they have no conflict of interest.

Consent Informed consent has been obtained from the patient’s parents for the case report and medical photographs used in this manuscript. All studies have been performed in accordance with the 1964 Declaration of Helsinki and its later amendments.

Contributor’s Statement Liza J McCann, Jo McPartland, George Kokai, Chris Bacon, Julian Verbov and Andrew Riordan were involved in direct patient care and/or diagnostic process, provided patient data, and reviewed and approved the manuscript.

Dawn Barge performed and interpreted the immunological investigations results for the manuscript, and reviewed and approved the manuscript.
Eduardo Calonje interpreted the histopathology findings of the skin biopsy, and reviewed and approved the manuscript.
Lisa Strain and David Bourn performed and interpreted the genetic mutation analysis, and reviewed and approved the manuscript.
Michael Wright was involved in direct patient care and diagnostic process, interpreted the skeletal radiography and genetic mutation analysis, and reviewed and approved the manuscript.
Mario Abinun was involved in direct patient care and diagnostic process, and wrote the manuscript.

References

1. Abinun M, Kaitila I, Casanova JL. Immunodeficiencies with associated manifestations of skin, hair, teeth, and skeleton. In: Ochs HD, Smith CIE, Puck JM, editors. Primary immunodeficiency diseases. A molecular and genetic approach. (2nd ed). Oxford University Press; 2007. pp. 513–24
2. Thiel CT, Mortier G, Kaitila I, Reis A, Rauch A. Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia–anauxetic dysplasia spectrum. Am J Hum Genet. 2007;81:519–29.
3. Thiel CT, Rauch A. The molecular basis of the cartilage-hair hypoplasia–anauxetic dysplasia spectrum. Best Pract Res Clin Endocrinol Metab. 2011;25:131–42.
4. Rogler LE, Kosmyna B, Moskowitz D, Bebawee R, Rahimzadeh J, Kutchko K, et al. Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage hair hypoplasia. Hum Mol Genet. 2013. doi:10.1093/hmg/ddt427.2013.
5. De la Fuente MA, Recher M, Rider NL, Strauss KA, Morton DH, Adair M, et al. Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia. J Allergy Clin Immunol. 2011;128(1):139–46.
6. Kavadas FD, Giliani S, Gu Y, Mazzolari E, Bates A, Pegioti E, et al. Variability of clinical and laboratory features among patients with ribonuclease mitochondrial RNA processing endoribonuclease gene mutations. J Allergy Clin Immunol. 2008;122:1178–84.
7. Bordon V, Gennery AR, Vandecruys E, Laureys G, Veys P, et al. Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation. Blood. 2010;116(1):27–35.
8. Notarangelo LD, Roifman CM, Giliani S. Cartilage-hair hypoplasia: molecular basis and heterogeneity of the immunologic phenotype. Curr Opin Allergy Clin Immunol. 2008;8:534–9.
9. Kwan A, Manning MA, Zollars LK, Hoyne HE. Marked variability in the radiographic features of cartilage-hair hypoplasia: case report and review of the literature. Am J Med Genet A. 2012;158A(11):2911–6.
10. Türkkan-Asal G, Alanay Y, Tunel-Özgür T, Zener M, Thiel C, Rauch A, et al. Mild clinical phenotype and subtle radiographic findings in an infant with cartilage-hair hypoplasia. Turk J Pediatr. 2009;51:493–6.
11. Makite O, Rajanite J, Kaitila I. Anaemia and macrocytosis—unrecognized features in cartilage-hair hypoplasia. Acta Paediatr. 1992;81:1026–9.
12. Petersen HJ, Smith AM. The role of the innate immune system in granulomatous disorders. Front Immunol. 2013;4:120. doi:10.3389/fimmu.2013.00120.
13. Roifman CM, Gu Y, Cohen A. Mutations in the RNA component of RNase mitochondrial RNA processing might cause Omenn syndrome. J Allergy Clin Immunol. 2006;117:897–903.
14. Gatti RA, Platt N, Pomerance HH, Hong R, Langer LO, Kay HEM, et al. Hereditary lymphopenic agammaglobulinemia associated with a distinctive form of short-limbed dwarfism and ectodermal dysplasia. J Pediatr. 1969;75(4):675–84.
15. Gotoff SP, Esterly NB, Gottbrath E, Liebner EJ, Lajvardi SR. Granulomatous reaction in an infant with combined immunodeficiency and short-limbed dwarfism. J Pediatr. 1972;80(6):1010–7.
16. Moshous D, Meyts I, Fraiting S, Janssen CEI, Debre M, Suarez F, et al. Granulomatous inflammation in cartilage-hair hypoplasia: risks and benefits of anti-TNF-a mAbs. J Allergy Clin Immunol. 2011;128:847–53.
17. Crahes M, Saugier-Véber P, Patrer S, Aziz M, Pirot N, Brasseur-Daudrue M, et al. Foetal presentation of cartilage hair hypoplasia with extensive granulomatous inflammation. Eur J Med Genet. 2013;56(7):365–70.
18. Taskinen M, Jeskanen L, Karjalainen-Lindsberg ML, Mäkitie A, Adair M, et al. Foetal presentation of cartilage hair hypoplasia with extensive granulomatous inflammation. Eur J Med Genet. 2013;56(7):365–70.
19. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–66.
20. Makite O, Pukkala E, Teppo L, Kaitila I. Increased incidence of cancer in patients with cartilage-hair hypoplasia. J Pediatr. 1999;134:315–8.
21. Liston A, Enders A, Siggs OM. Unravelling the association of partial T cell immunodeficiency and immune regulation. Nat Rev Immunol. 2008;8:545–58.
22. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol. 2011;2:54. doi:10.3389/fimmu.2011.00054.
23. Roifman CM, Sorneck R, Kavadas F, Pires L, Nahum A, Dalal I, et al. Defining combined immunodeficiency: need for a revised approach. J Allergy Clin Immunol. 2012;130:177–83.
24. Maggina P, Gennery AR. Classification of primary immunodeficiency: need for a revised approach. J Allergy Clin Immunol. 2013;131(2):292–4.